**Lay Description of Important Outcomes**

Our main progress so far has clarified that the B cell responses in our mouse triple negative breast cancer models help with killing metastasis. Moreover, we find evidence that these anti-metastatic B cell responses may mechanistically involve interactions with T cells to drive killing of metastatic cancer cells. However, we also find that tumor metastasis eventually evade these B cell responses over time. We will define the

underpinning biology in these B cell-tumor cell interactions to identify new therapeutic targets to sustain robust anti-metastatic B cell and immune responses. Thus, our study supported by METAvivor is well positioned for success in understanding and optimizing the operational mechanisms vital for curing metastatic disease.

This funding from METAvivor also helped us published a review in Cancer Research that defines the current understanding of the diverse roles that B cell subsets can play in metastasis:

* Ramos, Monika J., Asona J. Lui, and Daniel P. Hollern. "The evolving landscape of B cells in cancer metastasis." *Cancer Research* 83.23 (2023): 3835-3845.

This funding from METAvivor led to additional funding for our research into B cell function in metastasis. Namely, this has come in the form of a Susan G Komen Career Catalyst award to the Hollern lab.